HRP20020309A2 - Treatment of fatigue, head injury and stroke - Google Patents
Treatment of fatigue, head injury and stroke Download PDFInfo
- Publication number
- HRP20020309A2 HRP20020309A2 HR20020309A HRP20020309A HRP20020309A2 HR P20020309 A2 HRP20020309 A2 HR P20020309A2 HR 20020309 A HR20020309 A HR 20020309A HR P20020309 A HRP20020309 A HR P20020309A HR P20020309 A2 HRP20020309 A2 HR P20020309A2
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- nausea
- treatment
- noradrenaline
- stroke
- Prior art date
Links
- 206010019196 Head injury Diseases 0.000 title description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 42
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 42
- 229960002748 norepinephrine Drugs 0.000 claims description 40
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 38
- 206010028813 Nausea Diseases 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 33
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 31
- 230000008693 nausea Effects 0.000 claims description 31
- 230000002474 noradrenergic effect Effects 0.000 claims description 23
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 21
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 20
- 210000004556 brain Anatomy 0.000 claims description 18
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 18
- 229960002813 lofepramine Drugs 0.000 claims description 17
- 208000029028 brain injury Diseases 0.000 claims description 14
- 208000001640 Fibromyalgia Diseases 0.000 claims description 12
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 11
- 229960003914 desipramine Drugs 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 230000037326 chronic stress Effects 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 229960003770 reboxetine Drugs 0.000 claims description 7
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims description 7
- 230000035882 stress Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- 229930003779 Vitamin B12 Natural products 0.000 claims description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004688 venlafaxine Drugs 0.000 claims description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 230000003925 brain function Effects 0.000 claims description 3
- 235000020774 essential nutrients Nutrition 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 229960001058 bupropion Drugs 0.000 claims description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 2
- 229960002866 duloxetine Drugs 0.000 claims description 2
- GJJFMKBJSRMPLA-DZGCQCFKSA-N levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims description 2
- 229960004617 sapropterin Drugs 0.000 claims description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 4
- 241000894006 Bacteria Species 0.000 claims 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 229960005190 phenylalanine Drugs 0.000 description 32
- 230000000694 effects Effects 0.000 description 29
- 210000000627 locus coeruleus Anatomy 0.000 description 24
- 201000006417 multiple sclerosis Diseases 0.000 description 22
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- 229960004441 tyrosine Drugs 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 17
- 239000002243 precursor Substances 0.000 description 15
- 230000006378 damage Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 229940076279 serotonin Drugs 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 229940005513 antidepressants Drugs 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000006931 brain damage Effects 0.000 description 4
- 231100000874 brain damage Toxicity 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- -1 duloxentine Chemical compound 0.000 description 3
- 230000000586 effect on nausea Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009509 cortical damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229960000600 milnacipran Drugs 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 210000001587 telencephalon Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010068932 Terminal insomnia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000695 effect on serotonin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000027407 head symptom Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229950003041 levoprotiline Drugs 0.000 description 1
- FDXQKWSTUZCCTM-ZUIJCZDSSA-N levoprotiline Chemical compound C12=CC=CC=C2C2(C[C@@H](O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-ZUIJCZDSSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 210000004189 reticular formation Anatomy 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000001679 solitary nucleus Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Finger-Pressure Massage (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9924172A GB2355191A (en) | 1999-10-12 | 1999-10-12 | Combination formulations for fatigue, head injury and strokes |
| PCT/GB2000/003926 WO2001026623A2 (en) | 1999-10-12 | 2000-10-12 | Treatment of fatigue, head injury and stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20020309A2 true HRP20020309A2 (en) | 2004-02-29 |
Family
ID=10862624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020309A HRP20020309A2 (en) | 1999-10-12 | 2002-04-10 | Treatment of fatigue, head injury and stroke |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6441038B1 (de) |
| EP (1) | EP1220689B1 (de) |
| AU (1) | AU782656B2 (de) |
| CA (1) | CA2388377C (de) |
| CZ (1) | CZ20021197A3 (de) |
| DE (1) | DE60042598D1 (de) |
| GB (1) | GB2355191A (de) |
| HR (1) | HRP20020309A2 (de) |
| HU (1) | HUP0203470A3 (de) |
| MX (1) | MXPA02003724A (de) |
| NO (1) | NO20021716L (de) |
| NZ (1) | NZ518306A (de) |
| PL (1) | PL354975A1 (de) |
| SK (1) | SK4672002A3 (de) |
| WO (1) | WO2001026623A2 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60035232T2 (de) | 1999-07-01 | 2008-02-14 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| AU2003213009A1 (en) * | 2002-02-12 | 2003-09-04 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
| US20030176773A1 (en) * | 2002-03-12 | 2003-09-18 | Gendreau Roger Michael | Methods of assessing the level of a subjective symptom |
| PL223471B1 (pl) * | 2002-03-15 | 2016-10-31 | Cypress Bioscience Inc | Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego |
| AU2003225206B2 (en) * | 2002-04-24 | 2008-02-14 | Forest Laboratories Holdings Limited | Prevention and treatment of functional somatic disorders, including stress-related disorders |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| CA2483464C (en) * | 2002-05-17 | 2011-12-20 | Duke University | Method for treating obesity |
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| US20070129438A1 (en) * | 2002-07-11 | 2007-06-07 | Yuuichi Murayama | Method for suppressing proliferation of abnormal prion protein |
| MXPA05003550A (es) * | 2002-10-03 | 2006-01-24 | Cypress Bioscience Inc | Incremento de dosificacion y dosis diaria dividida de anti-depresivos para tratar padecimientos neurologicos. |
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| AU2003287499A1 (en) * | 2002-11-19 | 2004-06-15 | Eli Lilly And Company | Treatment of gastrointestinal disorders with duloxetine |
| CN100353946C (zh) * | 2003-01-13 | 2007-12-12 | 戴诺吉药品有限公司 | 治疗功能性肠病的方法 |
| MXPA05007379A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos. |
| MXPA05008652A (es) | 2003-02-14 | 2005-10-18 | Pf Medicament | Uso del enantiomero (1s,2r) de milnacipran para la preparacion de un medicamento. |
| FR2851163B1 (fr) | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| EP1539181B1 (de) | 2003-04-04 | 2007-06-27 | Dynogen Pharmaceuticals Inc. | Methode zur behandlung von erkrankungen der unteren harnwege |
| ES2303085T3 (es) | 2003-04-29 | 2008-08-01 | Orexigen Therapeutics, Inc. | Composiciones que afectan a la perdida de peso. |
| WO2004105690A2 (en) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Treatment of chronic pain associated with drug or radiation therapy |
| GB0313630D0 (en) * | 2003-06-12 | 2003-07-16 | Wwk Trust The | Compositions for the enhanced treatment of depression |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| ES2596827T3 (es) * | 2003-11-17 | 2017-01-12 | Biomarin Pharmaceutical Inc. | Tratamiento de la fenilcetonuria con BH4 |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| JP2007517901A (ja) | 2004-01-13 | 2007-07-05 | デューク・ユニバーシティー | 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物 |
| WO2005107806A1 (en) * | 2004-04-21 | 2005-11-17 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| CA2576505A1 (en) * | 2004-08-03 | 2006-02-16 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
| US20080261955A1 (en) * | 2004-10-01 | 2008-10-23 | Timothy Dinan | Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| WO2006063215A2 (en) * | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| BRPI0618918B8 (pt) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US20070179168A1 (en) * | 2005-11-28 | 2007-08-02 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| CA2631740A1 (en) * | 2005-12-05 | 2007-06-14 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of disease |
| WO2007088473A2 (en) * | 2006-02-03 | 2007-08-09 | Neurocure Ltd | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| JP2010503669A (ja) | 2006-09-12 | 2010-02-04 | アドラー コーポレーション | 認知機能の強化のためのｎ含有スピロ化合物の使用 |
| WO2008042773A2 (en) * | 2006-09-29 | 2008-04-10 | Pdxrx, Inc. | Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders |
| KR20190042766A (ko) | 2006-11-09 | 2019-04-24 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| WO2008089148A1 (en) * | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug |
| LT3461503T (lt) | 2007-04-11 | 2022-03-10 | Biomarin Pharmaceutical Inc. | Tetrahidrobiopterino, susijusių kompozicijų įvedimo būdai ir matavimo būdai |
| DK2792662T3 (da) | 2007-05-01 | 2016-07-25 | Concert Pharmaceuticals Inc | Morphinanforbindelser |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20120083487A1 (en) * | 2008-10-30 | 2012-04-05 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury |
| US8865937B2 (en) | 2009-11-06 | 2014-10-21 | Mahendra G. Dedhiya | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
| AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
| US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
| ES2626651T3 (es) * | 2011-06-24 | 2017-07-25 | K-Pax Pharmaceuticals, Inc. | Composiciones para el tratamiento de la fatiga crónica |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| RU2493839C1 (ru) * | 2012-02-28 | 2013-09-27 | Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека | Способ лечения синдрома хронической усталости |
| EP2858640B1 (de) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Zusammensetzung zur Verwendung in einem Verfahren zur Behandlung von Übergewicht und Fettleibigkeit in Patienten mit hohem Herz-Kreislauf-Risiko |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200237875A1 (en) * | 2019-01-30 | 2020-07-30 | Synlev Pharmaceuticals Corporation | Formulations and methods for treatment of fibromyalgia and related myofascial pain disorders |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431670A (en) * | 1980-12-19 | 1984-02-14 | Bernardo Heller | D-Phenylalanine treatment |
| US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
| ES2184808T3 (es) * | 1994-10-05 | 2003-04-16 | Cari Loder | Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12. |
| GB2297868B (en) | 1995-02-07 | 1999-04-28 | Nokia Mobile Phones Ltd | A shielding device |
| JP3128609B2 (ja) | 1996-02-01 | 2001-01-29 | 株式会社小糸製作所 | 車輌用灯具の照射方向制御装置 |
| AU3451797A (en) * | 1996-07-05 | 1998-02-02 | Andrew Peter Worsley | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
| US5765240A (en) * | 1996-07-31 | 1998-06-16 | L&P Property Management Co. | Spring bedding product collapsible in the transverse direction, and method of making it |
| GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| GB9618341D0 (en) * | 1996-09-03 | 1996-10-16 | Scotia Holdings Plc | Method of treatment |
-
1999
- 1999-10-12 GB GB9924172A patent/GB2355191A/en not_active Withdrawn
-
2000
- 2000-10-12 CA CA2388377A patent/CA2388377C/en not_active Expired - Fee Related
- 2000-10-12 NZ NZ518306A patent/NZ518306A/en not_active IP Right Cessation
- 2000-10-12 PL PL00354975A patent/PL354975A1/xx not_active Application Discontinuation
- 2000-10-12 WO PCT/GB2000/003926 patent/WO2001026623A2/en active IP Right Grant
- 2000-10-12 SK SK467-2002A patent/SK4672002A3/sk unknown
- 2000-10-12 DE DE60042598T patent/DE60042598D1/de not_active Expired - Lifetime
- 2000-10-12 EP EP00969670A patent/EP1220689B1/de not_active Expired - Lifetime
- 2000-10-12 HU HU0203470A patent/HUP0203470A3/hu unknown
- 2000-10-12 AU AU79328/00A patent/AU782656B2/en not_active Ceased
- 2000-10-12 MX MXPA02003724A patent/MXPA02003724A/es not_active Application Discontinuation
- 2000-10-12 US US09/686,629 patent/US6441038B1/en not_active Expired - Fee Related
- 2000-10-12 CZ CZ20021197A patent/CZ20021197A3/cs unknown
-
2002
- 2002-04-10 HR HR20020309A patent/HRP20020309A2/hr not_active Application Discontinuation
- 2002-04-11 NO NO20021716A patent/NO20021716L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU7932800A (en) | 2001-04-23 |
| GB2355191A (en) | 2001-04-18 |
| CZ20021197A3 (cs) | 2002-09-11 |
| NZ518306A (en) | 2004-04-30 |
| EP1220689B1 (de) | 2009-07-22 |
| WO2001026623A2 (en) | 2001-04-19 |
| WO2001026623A3 (en) | 2001-06-21 |
| HUP0203470A3 (en) | 2005-10-28 |
| CA2388377C (en) | 2011-02-01 |
| SK4672002A3 (en) | 2002-09-10 |
| GB9924172D0 (en) | 1999-12-15 |
| PL354975A1 (en) | 2004-03-22 |
| NO20021716L (no) | 2002-06-10 |
| AU782656B2 (en) | 2005-08-18 |
| EP1220689A2 (de) | 2002-07-10 |
| NO20021716D0 (no) | 2002-04-11 |
| HUP0203470A2 (hu) | 2003-02-28 |
| DE60042598D1 (de) | 2009-09-03 |
| CA2388377A1 (en) | 2001-04-19 |
| MXPA02003724A (es) | 2003-10-14 |
| US6441038B1 (en) | 2002-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020309A2 (en) | Treatment of fatigue, head injury and stroke | |
| Bhat et al. | Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders | |
| US11324733B2 (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| US6689816B2 (en) | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders | |
| Handy et al. | Pain in amyotrophic lateral sclerosis: a neglected aspect of disease | |
| Engel et al. | Alcohol: mechanisms along the mesolimbic dopamine system | |
| DE69931957T2 (de) | Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns-erkrankungen | |
| TWI816643B (zh) | 透過腦神經之藥理皮膚活化作用來治療與神經退化性疾病相關之症狀的技術 | |
| JP4562911B2 (ja) | 遅発性ジスキネジア及び他の運動障害の治療方法 | |
| Jones et al. | Brain damage, behavior, rehabilitation, recovery, and brain plasticity | |
| KR20150085510A (ko) | 정신 의학적 증상의 치료를 위한 ｄ-메타돈 | |
| Zhai et al. | Reducing complement activation during sleep deprivation yields cognitive improvement by dexmedetomidine | |
| CA2444269C (en) | Treatment of disorders secondary to organic impairments | |
| Huang et al. | New insights into the roles of oligodendrocytes regulation in ischemic stroke recovery | |
| NZ533370A (en) | Use of cetyl myristate and cetyl palmitate in therapy for multiple sclerosis | |
| AU2002258820A1 (en) | Treatment of disorders secondary to organic impairments | |
| TW448044B (en) | Pharmaceutical composition of selegiline for the treatment of epileptic disorders | |
| Yadav | Pharmacological Treatment of ADHD | |
| Mukand et al. | Olanzapine for the treatment of hemiballismus: A case report | |
| JP2024505283A (ja) | 遂行機能障害の処置のための併用療法 | |
| STAHL | WILLIAM M. SAUVé | |
| Tyagi et al. | EFFECT OF ADJUVANT ANTICHOLINESTERASE THERAPY FOR THE MANAGEMENT OR TREATMENT OF EPILEPSY. | |
| Sussman | Nicotine and schizophrenia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn |